Matches in SemOpenAlex for { <https://semopenalex.org/work/W1604087062> ?p ?o ?g. }
- W1604087062 endingPage "485" @default.
- W1604087062 startingPage "463" @default.
- W1604087062 abstract "Mibefradil is the prototype of a new class of calcium antagonists that selectively block T‐type voltage‐gated plasma membrane calcium channels in vascular smooth muscle. The drug is structurally and pharmacologically different from traditional calcium antagonists. It does not have negative inotropism at therapeutic concentrations, and is not associated with reflex activation of neurohormonal and sympathetic systems. In clinical studies of hypertension, mibefradil 50 and 100 mg/day reduced trough sitting diastolic and systolic blood pressures in a dose‐related manner. Dosages exceeding 100 mg/day generally did not result in significantly greater efficacy, but were associated with a higher frequency of adverse events. No first‐dose hypotensive phenomenon was observed. Mibefradil has antiischemic properties resulting from dilation of coronary and peripheral vascular smooth muscle, and a slight reduction in heart rate. In clinical studies of chronic stable angina pectoris, dose‐related increases in exercise duration, time to onset of angina, and time to 1‐mm ST‐segment depression during exercise tolerance tests occurred. Mibefradil reduced the number and duration of ischemic events recorded by 48‐hour ambulatory electrocardiograph (ECG) monitoring, as well as number of anginal episodes and nitroglycerin consumption. Favorable hemodynamic and clinical profiles are reported, including high trough:peak ratios (> 80%), high oral bioavailability, and long elimination half‐life (17–25 hrs) permitting once/day dosing. Dizziness, headache, leg edema, and lightheadedness are frequently reported, but overall the agent is well tolerated. First‐degree atrioventricular block and sinus bradycardia are the most frequent ECG changes caused by the drug. In vitro studies indicate mibefradil inhibits cytochrome P450 1A2, 2D6, and 3A4, resulting in elevated plasma concentrations of drugs metabolized by those isoenzymes. Therefore, it is contraindicated in patients receiving terfenadine, astemizole, cisapride, lovastatin, or simvastatin." @default.
- W1604087062 created "2016-06-24" @default.
- W1604087062 creator A5009618176 @default.
- W1604087062 creator A5062338789 @default.
- W1604087062 date "1998-05-06" @default.
- W1604087062 modified "2023-10-17" @default.
- W1604087062 title "Mibefradil, a Pharmacologically Distinct Calcium Antagonist" @default.
- W1604087062 cites W1808014463 @default.
- W1604087062 cites W1966980453 @default.
- W1604087062 cites W1968127966 @default.
- W1604087062 cites W1969967993 @default.
- W1604087062 cites W1977686015 @default.
- W1604087062 cites W1978610287 @default.
- W1604087062 cites W1980794949 @default.
- W1604087062 cites W1980955546 @default.
- W1604087062 cites W1982690791 @default.
- W1604087062 cites W1983128983 @default.
- W1604087062 cites W1983494586 @default.
- W1604087062 cites W1983782719 @default.
- W1604087062 cites W1984296194 @default.
- W1604087062 cites W1987416588 @default.
- W1604087062 cites W1989649753 @default.
- W1604087062 cites W1999596364 @default.
- W1604087062 cites W2004902639 @default.
- W1604087062 cites W2005781144 @default.
- W1604087062 cites W2010654277 @default.
- W1604087062 cites W2015360390 @default.
- W1604087062 cites W2022941827 @default.
- W1604087062 cites W2023213460 @default.
- W1604087062 cites W2023844015 @default.
- W1604087062 cites W2025136979 @default.
- W1604087062 cites W2027156597 @default.
- W1604087062 cites W2027157785 @default.
- W1604087062 cites W2029649344 @default.
- W1604087062 cites W2029676169 @default.
- W1604087062 cites W2033193289 @default.
- W1604087062 cites W2033601338 @default.
- W1604087062 cites W2034877370 @default.
- W1604087062 cites W2038460733 @default.
- W1604087062 cites W2040569221 @default.
- W1604087062 cites W2041526045 @default.
- W1604087062 cites W2042716907 @default.
- W1604087062 cites W2042964099 @default.
- W1604087062 cites W2046383587 @default.
- W1604087062 cites W2046725590 @default.
- W1604087062 cites W2049812116 @default.
- W1604087062 cites W2053798040 @default.
- W1604087062 cites W2053901143 @default.
- W1604087062 cites W2055452297 @default.
- W1604087062 cites W2064500978 @default.
- W1604087062 cites W2068617048 @default.
- W1604087062 cites W2070473979 @default.
- W1604087062 cites W2073647642 @default.
- W1604087062 cites W2074231791 @default.
- W1604087062 cites W2076835537 @default.
- W1604087062 cites W2086604757 @default.
- W1604087062 cites W2086942070 @default.
- W1604087062 cites W2088191572 @default.
- W1604087062 cites W2088505113 @default.
- W1604087062 cites W2088896056 @default.
- W1604087062 cites W2093538665 @default.
- W1604087062 cites W2101893325 @default.
- W1604087062 cites W2104187252 @default.
- W1604087062 cites W2107567093 @default.
- W1604087062 cites W2113324544 @default.
- W1604087062 cites W2114669282 @default.
- W1604087062 cites W2115522997 @default.
- W1604087062 cites W2118309627 @default.
- W1604087062 cites W2123663550 @default.
- W1604087062 cites W2124976155 @default.
- W1604087062 cites W2137946717 @default.
- W1604087062 cites W2142436969 @default.
- W1604087062 cites W2143192352 @default.
- W1604087062 cites W2163367728 @default.
- W1604087062 cites W2165627388 @default.
- W1604087062 cites W2170364275 @default.
- W1604087062 cites W2312388685 @default.
- W1604087062 cites W2318480619 @default.
- W1604087062 cites W2322805289 @default.
- W1604087062 cites W2327035211 @default.
- W1604087062 cites W2327865610 @default.
- W1604087062 cites W2328214427 @default.
- W1604087062 cites W2469805673 @default.
- W1604087062 cites W2585382523 @default.
- W1604087062 cites W3022929210 @default.
- W1604087062 cites W4210280888 @default.
- W1604087062 cites W4231250029 @default.
- W1604087062 cites W4245244523 @default.
- W1604087062 cites W4256032229 @default.
- W1604087062 cites W95791577 @default.
- W1604087062 doi "https://doi.org/10.1002/j.1875-9114.1998.tb03110.x" @default.
- W1604087062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9620098" @default.
- W1604087062 hasPublicationYear "1998" @default.
- W1604087062 type Work @default.
- W1604087062 sameAs 1604087062 @default.
- W1604087062 citedByCount "9" @default.
- W1604087062 countsByYear W16040870622012 @default.
- W1604087062 countsByYear W16040870622017 @default.